Comparing the current results to its competitors, Pulmonx reported Revenue decrease in the 2 quarter 2026 year on year by -1.93 %, despite the revenue increase by the most of its competitors of 12.2 %, recorded in the same quarter.
Pulmonx Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 20.91 %
Pulmonx's Comment on Competition and Industry Peers
The company competes with the Spiration Valve System, which is contraindicated for patients with homogeneous emphysema. The company cites stronger clinical data, differentiated patient selection tools, and comprehensive technical and reimbursement support as factors in its competitive positioning. Another competitor is the InterVapor System, a non-surgical and non-implant therapy for lung diseases including emphysema and lung cancer. The company acknowledges that other firms may acquire or in-license competitive products and compete directly. Additionally, the company has a cross-licensing agreement with Spiration, Inc., later acquired by Olympus Medical Systems Corp., to minimize conflicts as both developed products in the same field.
September 9, 2024
Pulmonx Unveils Groundbreaking Data on AeriSeal System at the European Respiratory Society Congress 2024 In a significant advance for patients suffering from chronic obstructive pulmonary disease (COPD), Pulmonx Corporation, a leader in the field of lung volume reduction technologies, has announced the presentation of pivotal clinical data from the AeriSeal CONVERT trial as well as five-year follow-up data from the LIBERATE study at the 2024 European Respiratory Society Congress. These findings underline the substantial effectiveness and safety profile of the AeriSeal System, offering renewed hope for patients with advanced emphysema. AeriSeal CONVERT Trial: A Transformative Approach to COPDThe CONVERT trial...
Merit Medical Systems Inc operates as a medical device company that develops, manufactures, and distributes disposable medical devices. Their business model focuses on delivering high-quality and innovative products to healthcare professionals and hospitals worldwide. They generate revenue through the sales and distribution of their medical devices, aiming to improve patient outcomes and provide value to healthcare providers.
Procept Biorobotics Corporation follows a business model focused on developing medical robotics solutions for urology procedures. Their flagship product, the AquaBeam System, utilizes waterjet technology to perform minimally invasive surgeries for patients with benign prostatic hyperplasia. The company aims to improve patient outcomes and reduce healthcare costs by providing an innovative and efficient alternative to traditional surgical methods.
Retractable Technologies Inc. is a medical device manufacturing company that specializes in the production of retractable needle systems. Their business model revolves around developing and distributing innovative safety medical products that protect healthcare workers from accidental needlestick injuries. By offering a range of retractable needle solutions, they aim to improve workplace safety and reduce the potential transmission of bloodborne diseases.
Sources:
Pulmonx Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pulmonx Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
